Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons

Lancet

Volumn 350, Issue 9077, 1997, Pages 556-559

  Hoet, Perrine ^a   Graf, Mary Louise M ^b,d   Bourdi, Mohammed ^b   Pohl, Lance R ^b   Duray, Paul H ^c   Chen, Weiqiao ^e   Peter, Raimund M ^e   Nelson, Sidney D ^e   Verlinden, Nicolas ^f   Lison, Dominique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHLOROFLUOROCARBON; CHLOROFLUOROHYDROCARBON; CYTOCHROME P450; HALOTHANE; OZONE; PROTEIN DISULFIDE ISOMERASE;

ADULT; ARTICLE; CASE REPORT; EPIDEMIC; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDUSTRIAL WORKER; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; LIVER NECROSIS; LIVER TOXICITY; MALE; METABOLISM; OCCUPATIONAL ACCIDENT; OCCUPATIONAL EXPOSURE; PORTAL VEIN; PRIORITY JOURNAL;

EID: 0030837070     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03094-8     Document Type: Article

References (17)

1. WHO. Environmental Health Criteria 139. Partially halogenated chlorofluorocarbons (ethane derivatives). Geneva: WHO, 1992.
2. Dekant W. Toxicology of chlorofluorocarbon replacements. Environ Health Perspect 1996; 104: 75-83.
3. Satoh H, Fukuda Y, Anderson DK, Ferrans JJ, Gillette JR, Pohl LR. Immunological studies on the mechanism of halothane-induced hepatotoxicity; immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther 1985; 233: 857-62.
4. Martin JL, Dubbink DA, Plevak DJ, et al. Halothane hepatitis 28 years after primary exposure. Anesth Analg 1992; 74: 605-08.
5. Kenna JG, Satoh H, Christ DD, Pohl LR. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane recognize neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988; 245: 1103-913.
6. Bourdi M, Demady D, Martin JL, et al. cDNA cloning and baculovirus expression of the human liver endoplasmic reticulum P58: characterization as a protein disulfide isomerase isoform, but not as a protease or a carnitine acyltransferase. Arch Biochem Biophys 1995; 323: 397-403.
7. Martin JL, Reed GF, Pohl LR. Association of anti-58 kDa endoplasmic reticulum bodies with halothane hepatitis. Biochem Pharmacol 1993; 46: 1247-50.
8. Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996; 9: 1159-66.
9. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996; 50: 573-82.
10. Marit GB, Dodd DE, George ME, Vinegar A. Hepatotoxicity in guinea pigs following acute inhalation exposure to 1,1-dichloro-2,2,2-trifluoroethane. Toxicol Pathol 1994; 22: 404-14.
11. Lind RC, Gandolfi AJ, Hall PM. Biotransformation and hepatotoxicity of HCFC 123 in the guinea-pig: potentiation of hepatic injury by prior glutathione depletion. Toxicol Appl Pharmacol 1995; 134: 175-81.
12. Rusch GM, Trochimovicz HJ, Malley LJ, et al. Subchronic inhalation toxicity studies with hydrochlorofluorocarbon 123 (HCFC 123). Fundam Appl Toxicol 1994; 23: 169-78.
13. Harris JW, Jones JP, Martin JL, et al. Pentahaloethane-based chlorofluorocarbon substitutes and halothane: correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic acid excretion with calculated enthalpies of activation. Chem Res Toxicol 1992; 5: 720-52.
14. Urban G, Speerschneider P, Dekant W. Metabolism of the chlorofluorocarbon substitute 1,1-dichloro-2,2,2-trichloroethane by rat and human liver microsomes: the role of cytochrome P450 2E1. Chem Res Toxicol 1994; 7: 170-76.
15. Vergani D, Mieli-Vergani G, Alberti A, et al. Antibodies to the surface of halothane altered hepatocytes in patients with severe halthane associated hepatitis. N Engl J Med 1980; 303: 66-71.
16. Kenna JG, Neuberger J, Williams R. Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J Pharmacol Exp Ther 1987; 242: 733-40.
17. Yin H, Anders M, Korzekwa K, et al. Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Proc Natl Acad Sci USA 1995; 92: 11076-80.